Background: Inpatient teledermatology (ITD) is a growing telemedicine modality aimed at addressing the shortage of dermatologists in hospitals, particularly for the management of complex skin disorders. Generalized pustular psoriasis (GPP) is a rare and potentially life-threatening condition characterized by widespread sterile pustules and systemic inflammation. Despite advances in targeted therapies, treatment is often limited to traditional agents such as cyclosporine and infliximab, due to restrictions in formulary access and insurance coverage.
Objective: This study aimed to characterize the clinical features, treatment outcomes, and the impact of ITD on the management of hospitalized GPP patients at the University of Pittsburgh Medical Center (UPMC), with a particular focus on hospitalization duration and time to pustule resolution.
Methods: A retrospective analysis of 35 patients with pustular skin disorders between January 2015 and August 2024 was conducted. Nine biopsy-confirmed GPP cases requiring hospitalization were included. Data on demographics, comorbidities, treatment regimens, and outcomes were collected. ITD consultations provided recommendations for corticosteroid tapering and immunosuppressive therapy initiation.
Results: The cohort included nine patients, predominantly White (88.9%), with a median age of 66 years. Preexisting psoriasis and obesity were the most common comorbidities (55.6%). Leukocytosis was the most frequent lab abnormality (77.8%). The average hospitalization duration was 6.1 ± 3.8 days, and readmission occurred in 33.3% of cases. ITD consultations led to early tapering of systemic corticosteroids and initiation of immunosuppressive therapy (55.6% with cyclosporine and 33.3% with infliximab). Significant pustule improvement was achieved in 16.1 ± 7.5 days, with full resolution in 22.5 ± 17.7 days.
Conclusion: ITD significantly reduced hospitalization duration for GPP patients compared with historical controls, likely due to timely therapeutic interventions. While newer biological therapies remain restricted in many hospitals, ITD facilitated the effective use of traditional immunosuppressive therapies, improving patient outcomes. This study supports the integration of ITD in hospital care models, especially in institutions lacking in-house dermatologists. Further research should explore long-term outcomes and the role of ITD in managing other emergent dermatologic conditions.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11839529 | PMC |
http://dx.doi.org/10.1089/tmr.2024.0068 | DOI Listing |
Drugs Context
March 2025
Cardiology Department, Arrhythmia Unit, University Hospital La Paz, Madrid, Spain.
Background: This analysis assesses the effectiveness and tolerability profile of vericiguat in patients with heart failure with reduced ejection fraction (HFrEF) and implantable cardioverter-defibrillator, with an emphasis on the emergence of ventricular arrhythmias.
Methods: Retrospective analysis of patients with HFrEF and implantable cardioverter-defibrillator who started treatment with vericiguat in daily clinical practice in a tertiary university hospital in Spain.
Results: The study population comprised 14 patients treated since January 2023.
Background And Aims: The primary objective of glycemic control in individuals with diabetes mellitus is to avert or postpone complications, which ultimately leads to an improved quality of life. Nonetheless, achieving the recommended targets for glycemic control in clinical settings often proves challenging. Consequently, it is crucial to ascertain factors that affect glycemic outcomes to enhance the management of diabetes mellitus.
View Article and Find Full Text PDFCureus
March 2025
Emergency Medicine, Nizwa Hospital, Nizwa, OMN.
Objective: This study aimed to observe changes in serum glucose levels following the administration of 50 mL of 50% dextrose solution (D50) in hypoglycemic patients. Specifically, we seek to determine the prevalence of rebound hyperglycemia episodes, the peak effect, and the duration of action of a single dose of 50 mL D50.
Method: This prospective observational study was conducted at four emergency departments (two tertiary care hospitals and two secondary care hospitals) in Oman over a three-year period, from May 1, 2019, to April 30, 2022.
Radiol Bras
February 2025
Department of Radiology, Medical Faculty, Ataturk University, Erzurum, Turkey.
Objective: To assess the frequency of unrecognized myocardial infarction and identify additional ischemic conditions, as well as to evaluate the efficacy of cardiac magnetic resonance imaging (CMRI) in risk groups, comparing the imaging findings with electro-cardiographic (ECG) and laboratory data in patients with stage 5 chronic kidney disease, also known as end-stage renal disease.
Materials And Methods: This was a prospective single-center study involving 20 patients who were referred to our radiology department to undergo CMRI between June 2010 and December 2011. Resting left ventricular functions and (early and late) myocardial contrast enhancement were assessed in all patients.
J Clin Aesthet Dermatol
February 2025
Drs. Desir, Encarnacion, and Mollanazar are with the Department of Dermatology at Perelman School of Medicine at the University of Pennsylvania in Philadelphia, Pennsylvania.
Objective: Oral Janus kinase inhibitors (JAKi) have demonstrated high levels of efficacy with acceptable safety in patients with atopic dermatitis (AD), yet there remains significant hesitancy among the dermatologic community to use JAKi in elderly populations due to the potential increased risk of serious adverse events in this population. We aimed to perform a retrospective review to describe real-world outcomes for the use of selective JAK-1 inhibitors in patients with AD aged 65 years or older.
Methods: We conducted a multicenter retrospective review.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!